110 related articles for article (PubMed ID: 2504680)
1. In vitro effects of an acyltripeptide, FK565, on NK-cell activity, LAK-cell generation and cytokine production by human mononuclear cells.
Wang YL; Whiteside TL; Friberg D; Herberman RB
Immunopharmacology; 1989; 17(3):175-85. PubMed ID: 2504680
[TBL] [Abstract][Full Text] [Related]
2. Decreased interleukin-15 from activated cord versus adult peripheral blood mononuclear cells and the effect of interleukin-15 in upregulating antitumor immune activity and cytokine production in cord blood.
Qian JX; Lee SM; Suen Y; Knoppel E; van de Ven C; Cairo MS
Blood; 1997 Oct; 90(8):3106-17. PubMed ID: 9376592
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.
McVicar DW; Merchant RE; Merchant LH; Young HF
Cancer Immunol Immunother; 1989; 29(3):211-8. PubMed ID: 2499421
[TBL] [Abstract][Full Text] [Related]
4. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer cells and cytokine production in humans by bacterial extracts (OM-85 BV).
Wybran J; Libin M; Schandene L
Lung; 1990; 168 Suppl():720-5. PubMed ID: 2117183
[TBL] [Abstract][Full Text] [Related]
6. Isolation of human NK cells and generation of LAK activity.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects of an acyltripeptide, FK565, on antitumor effector activities and on metabolic activities of human monocytes and granulocytes.
Wang YL; Kaplan S; Whiteside T; Herberman RB
Immunopharmacology; 1989; 18(3):213-22. PubMed ID: 2558091
[TBL] [Abstract][Full Text] [Related]
8. The regulation and biological activity of interleukin 12.
Lee SM; Suen Y; Qian J; Knoppel E; Cairo MS
Leuk Lymphoma; 1998 May; 29(5-6):427-38. PubMed ID: 9643557
[TBL] [Abstract][Full Text] [Related]
9. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis.
Cordingley FT; Hoffbrand AV; Brenner MK
Br J Haematol; 1988 Sep; 70(1):37-41. PubMed ID: 3140887
[TBL] [Abstract][Full Text] [Related]
11. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
12. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
13. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
[TBL] [Abstract][Full Text] [Related]
14. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors.
Cesano A; Oberholtzer E; Contarini M; Geuna M; Bellone G; Matera L
Immunopharmacology; 1994; 28(1):67-75. PubMed ID: 7928303
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity.
Hsu DH; Moore KW; Spits H
Int Immunol; 1992 May; 4(5):563-9. PubMed ID: 1627494
[TBL] [Abstract][Full Text] [Related]
16. In vitro combined effects of human interferons and interleukin-2 on natural cell-mediated cytotoxicity.
Fuggetta MP; Aquino A; Pepponi R; D'Atri S; Lanzilli G; Bonmassar E; Graziani G
Int J Immunopharmacol; 1993 Jan; 15(1):1-10. PubMed ID: 7679378
[TBL] [Abstract][Full Text] [Related]
17. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
18. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
19. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
20. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
